130 related articles for article (PubMed ID: 36286733)
1. [Extracorporeal cytokine removal in chimeric antigen receptor T-cell therapy associated cytokine release syndrome in patient with acute lymphoblastic leukemia. Case report].
Shchekina AE; Galstyan GM; Gavrilina OA; Arapova NM; Bronyakina SI; Kotova ES; Troitskaya VV; Parovichnikova EN; Maschan MA; Savchenko VG
Ter Arkh; 2021 Jul; 93(7):811-817. PubMed ID: 36286733
[TBL] [Abstract][Full Text] [Related]
2. Predictive role of endothelial cell activation in cytokine release syndrome after chimeric antigen receptor T cell therapy for acute lymphoblastic leukaemia.
Hong F; Shi M; Cao J; Wang Y; Gong Y; Gao H; Li Z; Zheng J; Zeng L; He A; Xu K
J Cell Mol Med; 2021 Dec; 25(24):11063-11074. PubMed ID: 34734474
[TBL] [Abstract][Full Text] [Related]
3. Investigation of the risk factors to predict cytokine release syndrome in relapsed or refractory B-cell acute lymphoblastic leukemia patients receiving IL-6 knocking down anti-CD19 chimeric antigen receptor T-cell therapy.
Gong WJ; Qiu Y; Li MH; Chen LY; Li YY; Yu JQ; Kang LQ; Sun AN; Wu DP; Yu L; Xue SL
Front Immunol; 2022; 13():922212. PubMed ID: 36105799
[TBL] [Abstract][Full Text] [Related]
4. The incidence of cytokine release syndrome and neurotoxicity of CD19 chimeric antigen receptor-T cell therapy in the patient with acute lymphoblastic leukemia and lymphoma.
Cao JX; Wang H; Gao WJ; You J; Wu LH; Wang ZX
Cytotherapy; 2020 Apr; 22(4):214-226. PubMed ID: 32305113
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of CD19 CAR-T cell therapy for patients with B cell acute lymphoblastic leukemia involving extramedullary relapse.
Huang L; Zhang M; Wei G; Zhao H; Hu Y; Huang H
Zhejiang Da Xue Xue Bao Yi Xue Ban; 2022 Apr; 51(2):151-159. PubMed ID: 36161297
[TBL] [Abstract][Full Text] [Related]
6. Anti-CD19 chimeric antigen receptor T-cell therapy in acute lymphocytic leukaemia: a systematic review and meta-analysis.
Anagnostou T; Riaz IB; Hashmi SK; Murad MH; Kenderian SS
Lancet Haematol; 2020 Nov; 7(11):e816-e826. PubMed ID: 33091355
[TBL] [Abstract][Full Text] [Related]
7. [Three cases of hemodiafiltration for the treatment of CAR-T related grade 3 - 4 cytokine release syndrome after ineffective treatment with IL-6 receptor inhibitors].
Chen SY; Chen WH; Wan XC; Du X; Luo CR; Li XQ; Zhang XH
Zhonghua Xue Ye Xue Za Zhi; 2022 Jun; 43(6):494-498. PubMed ID: 35968593
[No Abstract] [Full Text] [Related]
8. Case Report: Local Cytokine Release Syndrome in an Acute Lymphoblastic Leukemia Patient After Treatment With Chimeric Antigen Receptor T-Cell Therapy: A Possible Model, Literature Review and Perspective.
Luan C; Zhou J; Wang H; Ma X; Long Z; Cheng X; Chen X; Huang Z; Zhang D; Xia R; Ge J
Front Immunol; 2021; 12():707191. PubMed ID: 34349766
[TBL] [Abstract][Full Text] [Related]
9. Individual Patient Data Meta-Analysis from 16 Trials for Safety Factors in Cytokine Release Syndrome After CAR-T Therapy in Patients with Non-Hodgkin Lymphoma (NHL) and Acute Lymphoblastic Leukemia.
Li J; Wu Z; Zhao N
Adv Ther; 2019 Oct; 36(10):2881-2894. PubMed ID: 31428935
[TBL] [Abstract][Full Text] [Related]
10. Systematic Review and Meta-analysis of CD19-Specific CAR-T Cell Therapy in Relapsed/Refractory Acute Lymphoblastic Leukemia in the Pediatric and Young Adult Population: Safety and Efficacy Outcomes.
Aamir S; Anwar MY; Khalid F; Khan SI; Ali MA; Khattak ZE
Clin Lymphoma Myeloma Leuk; 2021 Apr; 21(4):e334-e347. PubMed ID: 33573914
[TBL] [Abstract][Full Text] [Related]
11. Early granulocyte colony stimulating factor administration increases the risk of cytokine release syndrome in acute lymphoblastic leukemia patients receiving anti-CD19 chimeric antigen receptor T-cell therapy.
Cao M; Han S; Qiu Y; Zhou L; Su Y; Tu S; Li Y
Hematol Oncol; 2023 Dec; 41(5):933-941. PubMed ID: 37259483
[TBL] [Abstract][Full Text] [Related]
12. Plasma Exchange Can Be an Alternative Therapeutic Modality for Severe Cytokine Release Syndrome after Chimeric Antigen Receptor-T Cell Infusion: A Case Report.
Xiao X; He X; Li Q; Zhang H; Meng J; Jiang Y; Deng Q; Zhao M
Clin Cancer Res; 2019 Jan; 25(1):29-34. PubMed ID: 30322878
[TBL] [Abstract][Full Text] [Related]
13. Using JAK inhibitor to treat cytokine release syndrome developed after chimeric antigen receptor T cell therapy for patients with refractory acute lymphoblastic leukemia: A case report.
Zi FM; Ye LL; Zheng JF; Cheng J; Wang QM
Medicine (Baltimore); 2021 May; 100(19):e25786. PubMed ID: 34106613
[TBL] [Abstract][Full Text] [Related]
14. Management of cytokine release syndrome after chimeric antigen T-cell therapy for paediatric relapsed/refractory acute lymphoblastic leukaemia: a case report.
Cheng FWT; Li BS; Lam GKS; Hon KL; Joynt G; Li CK
Hong Kong Med J; 2020 Dec; 26(6):532-534. PubMed ID: 33350967
[No Abstract] [Full Text] [Related]
15. Chimeric antigen receptor T-cell therapy in adults with B-cell acute lymphoblastic leukemia.
Grover P; Veilleux O; Tian L; Sun R; Previtera M; Curran E; Muffly L
Blood Adv; 2022 Mar; 6(5):1608-1618. PubMed ID: 34610109
[TBL] [Abstract][Full Text] [Related]
16. Cytokine release syndrome and complete remission of extra medullary acute lymphoblastic leukemia of the breast with CAR-T and radiation therapy.
Ragoonanan D; Tambaro FP; Khazal SJ; Tewari P; Petropoulos D; Champlin R; Mahadeo KM
Pediatr Blood Cancer; 2021 May; 68(5):e28839. PubMed ID: 33258192
[No Abstract] [Full Text] [Related]
17. Timing of Tocilizumab Administration Under the Guidance of IL-6 in CAR-T Therapy for R/R Acute Lymphoblastic Leukemia.
Zhang Y; Zhou F; Wu Z; Li Y; Li C; Du M; Luo W; Kou H; Lu C; Mei H
Front Immunol; 2022; 13():914959. PubMed ID: 35799791
[TBL] [Abstract][Full Text] [Related]
18. The severe cytokine release syndrome in phase I trials of CD19-CAR-T cell therapy: a systematic review.
Jin Z; Xiang R; Qing K; Li X; Zhang Y; Wang L; Zhu H; Mao Y; Xu Z; Li J
Ann Hematol; 2018 Aug; 97(8):1327-1335. PubMed ID: 29766234
[TBL] [Abstract][Full Text] [Related]
19. Cytokine Release Syndrome With the Novel Treatments of Acute Lymphoblastic Leukemia: Pathophysiology, Prevention, and Treatment.
Aldoss I; Khaled SK; Budde E; Stein AS
Curr Oncol Rep; 2019 Jan; 21(1):4. PubMed ID: 30666425
[TBL] [Abstract][Full Text] [Related]
20. Evidence of long-lasting anti-CD19 activity of engrafted CD19 chimeric antigen receptor-modified T cells in a phase I study targeting pediatrics with acute lymphoblastic leukemia.
Ma F; Ho JY; Du H; Xuan F; Wu X; Wang Q; Wang L; Liu Y; Ba M; Wang Y; Luo J; Li J
Hematol Oncol; 2019 Dec; 37(5):601-608. PubMed ID: 31465532
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
